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Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and
Food Allergens (NDA) was asked to deliver an opinion on the safety of Schizochytrium sp. oil as a
novel food (NF) pursuant to Regulation (EU) 2015/2283. Schizochytrium sp. is a single-cell microalga.
The strain WZU477, used by the applicant (Progress Biotech bv), was found to belong to the species
Schizochytrium limacinum and was obtained in a marine environment from rotted mangrove forest
leaves. The NF, an oil rich in docosahexaenoic acid (DHA), is isolated from the microalgae by
mechanical extraction. The applicant proposed to use the NF in infant formulae (IF) and follow-on
formulae (FOF). The use level defined by the applicant was derived from Regulation (EU) 2016/127,
which states the mandatory addition of DHA to IF and FOF at the level of 20–50 mg/100 kcal. The
intake of DHA resulting from the use of the NF in IF and FOF is not expected to pose safety concerns.
The composition of the NF indicates the absence of marine biotoxins in the NF. Furthermore,
Schizochytrium limacinum was attributed the qualified presumption of safety (QPS) status with the
qualification ‘for production purposes only’. Based on the information provided, the microalga is not
expected to survive the manufacturing process. Toxicological tests conducted with the NF were not
performed. However, based on the available toxicological data on various forms of oils derived from
Schizochytrium sp., the QPS status of the source of the NF, the production process and the
composition of the NF, the Panel considers there are no concerns with regard to toxicity of the NF. The
Panel concludes that the NF is safe under the proposed conditions of use.
© 2020 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Schizochytrium sp. oil is authorised, in accordance with Regulation (EC) No 258/971, as a novel
food for a number of uses as listed in Commission Implementing Regulation (EU) 2017/24702
establishing the Union list of novel foods in accordance with Regulation (EU) 2015/22833.
On 14 March 2019, the company Progress Biotech bv submitted a request to the European
Commission in accordance with Article 10 of Regulation (EU) 2015/2283 for an extension of use of
Schizochytrium sp. oil as a novel food. The applicant requests to extend the use of Schizochytrium sp. oil
to additional food categories, namely, infant formulae, follow-on formulae and fruit/vegetable puree. The
applicant has also requested data protection under Article 26 of Regulation (EU) 2015/2283.
In accordance with Article 10(3) of Regulation (EU) 2015/2283, the European Commission asks the
European Food Safety Authority to provide a scientific opinion on Schizochytrium sp. oil.
1.2. Interpretation of the Terms of Reference
The request of the European Commission is to provide a scientific opinion on the extension of use for
the NF Schizochytrium sp. oil (already authorised). Therefore, it was the interpretation of the Panel that
only new uses requested by the applicant shall be assessed in the present opinion. It was noted by the
Commission and by the Panel that the use of the NF in fruit/vegetable puree (100 mg/100 g) was already
authorised. Therefore, this use was not assessed in the present opinion. Only the uses in infant formulae
and follow-on formulae were assessed.
1.3. Information on existing evaluations and authorisations
Five existing evaluations of the NDA Panel of EFSA need to be mentioned:
• In the Scientific Opinion on Dietary Reference Values for fats (EFSA NDA Panel, 2010), the
NDA Panel set an adequate intake (AI) of 250 mg for eicosapentaenoic acid (EPA) plus
docosahexaenoic acid (DHA) for adults; an AI of 100 mg DHA for infants (> 6 months) and
young children < 24 months; and increased by 100–200 mg preformed DHA in addition to the
AI for adults as an adequate supply of n-3 long-chain PUFA during pregnancy and lactation.
• In the Scientific Opinion related to the tolerable upper intake level of eicosapentaenoic acid
(EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA) (EFSA NDA Panel,
2012), the Panel concluded that a tolerable upper intake level for DHA could not be
established. However, it was demonstrated that supplemental intakes of EPA and DHA
combined at doses up to 5 g/day, and supplemental intakes of EPA alone up to 1.8 g/day, do
not raise safety concerns for the adult population. The Panel also considered that supplemental
intakes of DHA alone up to about 1 g/day do not raise safety concerns for the general
population. Limited data were available on the effects of long-term supplementation with DHA
alone at higher doses.
• In the Scientific Opinion on nutrient requirements and dietary intakes of infants and young
children in the European Union (EFSA NDA Panel, 2013), the Panel concluded on the levels of
nutrient and energy intakes that are considered adequate for the majority of infants and young
children. In particular, the adequate intake for DHA of 100 mg/day was confirmed for infants
and young children between 6 and 24 months and was also applied to infants in the period
0–6 months, taking into account the concentration of essential fatty acids (including DHA) in
human breast milk. It is noted that there is no AI for DHA set for children after 24 months.
• In the Scientific Opinion on the essential composition of infant and follow-on formulae (EFSA
NDA Panel, 2014a), the Panel concluded that DHA should be added to infant formulae (IF) and
follow-on formulae (FOF) due to its structural role in the nervous tissue and the retina and its
1 Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and
novel foods ingredients. OJ L 43, 14.2.1997, p. 1.
2 Commission Implementing Regulation (EU) 2017/2470 of 20 December 2017 establishing the Union list of novel foods in
accordance with Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods. OJ L
351,30.12.2017, p. 72.
3 Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on novel foods, amending
Regulation (EU) No 1169/2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the
European Parliament and of the Council and Commission Regulation (EC) No 1852/2001. OJ L 327, 11.12.2015, p. 1.
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involvement in normal brain and visual development, the need of the developing brain to
accumulate large amounts of DHA in the first 2 years of life and the consideration that the intake
of preformed DHA generally results in an erythrocyte DHA status more closely resembling that of
a breast-fed infant than is achieved with alpha linolenic acid (ALA) alone. A range for the
recommended concentration of DHA in IF and FOF was derived: from 20 mg/100 kcal (4.8 mg/
100 kJ), based on the adequate intake of DHA (100 mg/day) and an average energy intake of
500 kcal/day, to 50 mg/100 kcal (12 mg/100 kJ), based on the highest observed DHA
concentration in human milk (1% DHA in fatty acids (FAs) and the amount of FA in human milk).
• In the Scientific Opinion on the extension of use for DHA and EPA-rich algal oil from
Schizochytrium sp. as a NF ingredient (EFSA NDA Panel, 2014b), it was concluded that the use
of the NF in food supplements up to a maximum DHA and EPA content of 3 g per daily dose
for the adult population, excluding pregnant and lactating women, was safe for the consumer.
2. Data and methodologies
2.1. Data
The safety assessment of this NF is based on data supplied in the application and information
submitted by the applicant following EFSA requests for supplementary information. In addition,
information provided by the EFSA Panel on Biological Hazards has also been considered (EFSA BIOHAZ
Panel, 2020).
Administrative and scientific requirements for NF applications referred to in Article 10 of Regulation
(EU) 2015/2283 are listed in the Commission Implementing Regulation (EU) 2017/24694.
A common and structured format on the presentation of NF applications is described in the EFSA
Guidance on the preparation and presentation of an NF application.5 As indicated in this Guidance, it is
the duty of the applicant to provide all of the available (proprietary, confidential and published) scientific
data, including both data in favour and not in favour to supporting the safety of the proposed NF.
This NF application includes a request for the protection of proprietary data.
2.2. Methodologies
The assessment follows the methodology set out in the EFSA Guidance on NF applications (EFSA NDA
Panel, 2016) and the principles described in the relevant existing guidance documents from the EFSA
Scientific Committee. The legal provisions for the assessment are laid down in Article 11 of Regulation
(EU) 2015/2283 and in Article 7 of the Commission Implementing Regulation (EU) 2017/2469.
This assessment concerns only risks that might be associated with consumption of the NF under




The NF, which is the subject of the application, is the ‘Schizochytrium sp. oil’. It is produced by the
microalgae Schizochytrium sp. (strain WZU477). With reference to article 3 of the NF Regulation 2015/
2283, the NF falls under the category 2(a)(ii): ‘food consisting of, isolated from or produced from
microorganisms, fungi or algae’. The production process involves the controlled growth of this alga
followed by the extraction and refinement of the oil produced by the algae. The oil is a mixture of
triglycerides containing polyunsaturated fatty acids (PUFA) in which docosahexaenoic acid (DHA)
represents more than 40% of total fatty acids. The NF is proposed to be used as an ingredient in
infant formulae (IF) and follow-on formulae (FOF).
4 Commission Implementing Regulation (EU) 2017/2469 of 20 December 2017 laying down administrative and scientific
requirements for applications referred to in Article 10 of Regulation (EU) 2015/2283 of the European Parliament and of the
Council on novel foods. OJ L 351, 30.12.2017, pp. 64–71.
5 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), Turck D, Bresson J-L, Burlingame B, Dean T,
Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle H, Naska A, Neuh€auser-Berthold M, Nowicka G, Pentieva
K, Sanz Y, Siani A, Sj€odin A, Stern M, Tome D, Vinceti M, Willatts P, Engel K-H, Marchelli R, P€oting A, Poulsen M, Salminen S,
Schlatter J, Arcella D, Gelbmann W, de Sesmaisons-Lecarre A, Verhagen H and van Loveren H, 2016. Guidance on the preparation
and presentation of an application for authorisation of a novel food in the context of Regulation (EU) 2015/2283. EFSA Journal
2016;14(11):4594, 24 pp. https://doi.org/10.2903/j.efsa.2016.4594
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3.2. Identity of the NF
The NF under assessment in the present application is an oil rich in docosahexaenoic acid (DHA). The
usual names to define this NF are ‘Schizochytrium sp. oil’, ‘DHA-rich oil from Schizochytrium’ or ‘DHA-rich
algal oil’. The oil produced by Progress Biotech bv is a formulation containing around 44% DHA.
The NF is isolated from marine microalgae belonging to the genus of Schizochytrium. The
taxonomic classification of the microalgae is commonly defined as follows: Kingdom: Chromista;
Phylum: Bigyra; Class: Labyrinthula; Order: Thraustochytriida; Family: Thraustochytriaceae; Genus:
Schizochytrium.
Some databases refer to the taxonomy Eukaryota, stramenopiles instead of mentioning the
Kingdom (Chromista) and the Phylum (Bigyra). Nevertheless, this is still leading to the class of
Labyrinthula (https://www.uniprot.org/taxonomy/2163902). Furthermore, the taxonomic classification
of the genus Schizochytrium has been subject to discussions in 2007 (Yokohama and Honda, 2007).
Based on genetic and phenotypic analysis, the authors proposed changes in the classification. The
genus Schizochytrium was amended and new genera like Aurantiochytrium and Oblongichytrium were
defined. Therefore, the genus Schizochytrium can now also be referred to as Aurantiochytrium.
In the present application, it is specified that the strain ‘WZU477’ is used to produce the NF. The
applicant clarified that this strain was obtained in a marine environment from rotted mangrove forest
leaves. The strain Schizochytrium WZU477 is deposited at the China General Microbiological Culture
Collection Centre under the reference number 1730 with an associated patent under the number
1916156 published by the Chinese patent office State Intellectual Property Office of the People’s
Republic of China (SIPO) in 2007. The strain WZU477 was selected without use of radiation, mutagenic
agents or genetic modifications.
The identity of the strain WZU477 was addressed by the applicant based on the comparison of
sequences of the 18S small subunit of ribosomal DNA (18S SSU-rDNA) gene. According to this
analysis, the genetic sequence of the 18S rDNA gene of WZU477 presents 98% homology with the
species Schizochytrium limacinum (based on 1,800 base pairs coding for 18S ribosomal RNA (rRNA)).
In addition, the morphology of the cells observed using electron microscopy corroborates this
conclusion. This information was previously assessed in the Netherlands by the Committee on Safety
Assessment of Novel Foods (VNV Committee) (CBG-Meb, 2014), which concluded that the applicant
had provided sufficient evidence to support the assumption that the strain WZU477 belongs to the
species Schizochytrium limacinum. It is noted that Schizochytrium limacinum is a synonym of
Aurantiochytrium limacinum.
3.3. Production process
The NF is produced according to the Food Safety System Certification (FSSC) 22000, which includes
hazard analysis critical control points (HACCP) principles.
The unicellular microalgae Schizochytrium sp. (WZU477) are grown under controlled conditions
(time, temperature, pH and aeration) in a liquid culture medium containing the necessary nutrients.
The cultivation process starts in the laboratory. The production method and the control and verification
processes ensure that the algae used in the production are pure cultures. The water used for the
controlled growth of the microalgae and throughout the production process is food grade and
conforms to food standard as required by ISO 22000. The applicant stated that the implemented steps
ensure that the water does not contain any marine biotoxins or other compounds of concern for
consumer safety. Quality control evaluations are performed at each stage of production in accordance
with FSSC 22000 (which includes HACCP).
The microalgae cells are harvested from the liquid medium by centrifugation (on batch production
basis). The harvested cells are immediately dried, and the oil is extracted. The cells lysis is carried out
mechanically, using a high-pressure homogenising machine and a sand mill machine. The oil is
subsequently concentrated by an additional centrifugation step to separate the oil fraction from the
water and non-oil fraction. The crude oil is subsequently filtered and refined (decolouration and
deodorisation using high temperature). At different steps of the process, authorised antioxidants are
added to ensure stability. At final stage, the production process involves a standardisation step to
reach the target concentration of DHA in the NF; a variable amount of ‘high oleic sunflower oil’ may
therefore be added to the oil produced from the algae. The NF is finally packaged and stored at a
temperature of –18°C.
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Considering the high temperature and duration of certain steps of the production process (e.g.
deodorisation and decolouration), viable cells are not expected to remain in the NF. The
Panel considers that the microalga is not expected to survive the manufacturing process.
The Panel considers that the production process is sufficiently described and does not raise safety
concerns.
The NF produced by the applicant is an oil which may undergo further processing steps (e.g.
powdering) to be used as an ingredient of infant formulae and follow-on formulae. However, these
steps are not carried out by the applicant, but by manufacturers of infant and follow-on formulae (see
also Section 3.4.1 Stability of the NF under the intended conditions of use). Therefore, the description
of the production process ends with the packaging and storing of the NF in its liquid/oily form.
3.4. Compositional data
The NF consists of triglycerides containing PUFA in which DHA is the predominant one.
In order to confirm that the manufacturing process is reproducible and adequate to produce a
product with the required characteristics on a commercial scale, the applicant provided analytical
information for six independent newly produced batches of the NF (40% Standard formulation)
(Tables 1a and 1b). Information was provided on the accreditation of the laboratories that
conducted the analyses presented in the application.
The proximate analytical results show that the NF is almost entirely composed of crude fat
(98.7–99.7%). The remainder of the NF is composed of ash, moisture and volatiles. Levels of fibre
and proteins in the NF are below the limit of quantification (LOQ) and the calculated carbohydrate
content of the oil is below 1%.
The batch to batch analysis indicates a good repeatability of the production process. A slight
variability of certain fatty acids (e.g. oleic acid ranging from 4.3% to 16.5% FA) was observed. This is
explained by the use of a variable amount of ‘high oleic sunflower oil’ for the standardisation of the NF
with respect to DHA. The DHA content in the NF (40.5–46.3% FA) is consistent through the six
batches.
The composition of the NF can be compared to the composition of the two other NFs based on
DHA-rich oil from Schizochytrium currently on the Union list and authorised for uses in IF and FOF:
‘Schizochytrium sp. (ATCC PTA-9695) oil’ and ‘Schizochytrium sp. (T18) oil’. Compositional data for
these NFs are available in the dossiers previously assessed by national authorities and submitted by
DSM (2013) and Mara Renewable (2016). A comparison of the main long-chain (n-3) PUFA relevant in
marine oils (DHA, EPA and DPA) was made. In the present NF, the average DHA content (44.2% of
FA) is comparable to the DHA content of the two other NFs, which ranged between 37.1% and 44.4%
of total FA. However, ‘Schizochytrium sp. (ATCC PTA-9695) oil’ and ‘Schizochytrium sp. (T18) oil’
contain higher levels of EPA (average 6 and 1.3% FA, respectively) compared to the oil from
Schizochytrium WZU477 (average 0.56% FA). Regarding DPA (n-3), concentration is very low in the
NF (0.1% FA), which is also the case in the two other NFs (< 1% FA).
Total sterol concentration varied between the different batches of the NF (3,470–5,097 mg/kg fat)
but remains within the natural variation commonly observed in different types of oil (Yang et al.,
2019). Furthermore, the concentration of sterols in the NF is lower than those measured in the
authorised DHA oil from ‘Schizochytrium sp. (ATCC PTA-9695)’ (5,100–5,600 mg/kg).
In terms of chemical contaminants and microbiological content, the composition of DHA oil from
Schizochytrium WZU477 does not present any differences from ‘Schizochytrium sp. (ATCC PTA-9695)
oil’ and ‘Schizochytrium sp. (T18) oil’. The concentrations of metals (< LOQs), mycotoxins (< LOQ),
polycyclic aromatic hydrocarbons (< LOQ), pesticide residues (< LOQ), PCBs, dioxins and glycidyl fatty
acid esters found in this batch to batch analysis are within the EU limits established in the respective
regulations and do not present concerns from a safety point of view. The concentrations of two
contaminants (glycidyl fatty acid esters and 3-MCPD (3-monochloro-propanol-1,2-diol) fatty acid
esters) exceeded the LOQ in two batches out of six. The refinement of the oil (including a
deodorisation step at high temperature) can lead to the formation of such compounds in oils and these
contaminants are currently regulated. For glycidyl fatty acid esters (expressed as glycidol), the maximum
level (ML) in IF and FOF (liquid) is 6 lg/kg. For 3-MCPD (sum of 3-MCPD and 3-MCPD fatty acid esters,
expressed as 3-MCPD), a draft regulation is close to adoption and will set an ML of 15 lg/kg in IF and
FOF (liquid). The MLs for these contaminants are expected to be respected in the final product (IF and
FOF) considering the incorporation rate of the NF in IF and FOF (max 87.5 mg NF/100 mL).
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Upon request for additional data, the applicant provided analyses of common marine biotoxins in
five independent batches of the NF (see Table 1b). These results indicate that marine biotoxins
remain below the respective limits of quantification (LOQ) in all samples. These data confirm the
assumption that the NF, produced from Schizochytrium sp. (strain WZU477), is not expected to contain
marine biotoxins, neither produced by the source organism (for which a QPS status was concluded)
nor from external contamination (considering the description of the production process in Section 3.3).
The Panel considers that the information provided on the composition of the NF is sufficient and
does not raise safety concerns.
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Table 1a: Batch to batch analysis of the NF (40% standard), PROXIMATE ANALYSIS and PHYSICO-CHEMICAL PARAMETERS
Parameter (unit)
Batch number
PB15232.3 PB16940715 NS-8107.2 PB19284.L NS-9127 NS-9126
Proximate analysis
Fat (g/100 g) 99.2 98.7 99.4 98.9 99.7 99.7
Proteins (g/100 g) < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
Carbohydrates (g/100 g) < 1 < 1 < 1 < 1 < 1 < 1
Crude ash (g/100 g) 0.01 0.02 0.03 0.02 0.02 0.01
Crude fibre (g/100 g) < 0.5 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5
Physico-chemical parameters
p-anisidine value 5.5(a) 5.9 4.3 2.9 2.6–2.8(b) 1.7–2.6(b)
Moisture & volatiles (%) 0.01 0.01 < 0.01 0.02 0.02 0.02
Unsaponifiable matter (%) 1.16 1.29 0.54 1.07 0.28 0.28
Acid value (mg KOH/g) 0.08 0.12 0.12 0.08 0.22–0.28(b) 0.14–0.28(b)
Peroxide value (meq/kg) 1(a) 0 0 0 0–4.8(b) 0–4.8(b)
Volumic mass (kg/L) 0.9318 0.936 0.935 0.9333 0.9344 0.9344
(a): For batch PB15232.3, p-anisidine value and peroxide value were measured by two different external labs in 2015 and 2020. The results obtained closest to production date (March 2015) were
retained in the table, noting that higher results were found in the new analysis performed in 2020 (11.9 and 4.6 meq/kg, respectively).
(b): For batches NS-9127 and NS-9126, p-anisidine value, acid value and peroxide value were measured by two different external labs. Both measurements were equally performed close to
production; thus, both results were reported in the table.
Table 1b: Batch to batch analysis of the NF (40% standard)
Parameter (unit)
Batch number
PB15232.3 PB16940715 NS-8107.2 PB19284.L NS-9127 NS-9126
Fatty acids (%FA)
Myristic – 14:0 0.5 0.5 0.7 0.7 0.7 0.7
Pentadecanoic – 15:0 0.1 0.1 0.1 0.3 0.1 0.1
Palmitic – 16:0 26.9 21.9 33.2 22.7 23.2 22.3
Palmitoleic – 16:1 (hexadecenoic 16:1 total) 0.2 0.3 0.2 0.3 0.3 0.3
Margaric – 17:0 0.1 0.1 0.1 0.2 0.2 0.1
Heptadecenoic – 17:1 0.2 0.3 0.2 – 0.1 0.3
Stearic – 18:0 1.8 1.5 1.5 1.5 1.4 1.3
Safety of Schizochytrium sp. oil as a novel food pursuant to Regulation (EU) 2015/2283
www.efsa.europa.eu/efsajournal 9 EFSA Journal 2020;18(10):6242
Parameter (unit)
Batch number
PB15232.3 PB16940715 NS-8107.2 PB19284.L NS-9127 NS-9126
Oleic – 18:1(n-9) 15.9 12.3 4.3 16.5 13.4 13
Cis-vaccenic – 18:1(n-7) 0.3 0.3 0.2 0.4 0.4 0.4
Linoleic – 18:2(n-6) 2.5 2.3 0.5 0.7 1.9 1.8
c-Linolenic – 18:3(n-6) 0.1 0.1 0.1 0.1 0.1 0.1
a-Linolenic – 18:3(n-3) 0.1 0.2 0.1 0.1 0.1 0.2
Stearidonic –18:4(n-3) 0.1 0.2 0.2 0.2 0.2 0.2
Arachidic – 20:0 0.2 0.2 0.2 0.2 0.2 0.2
Icosenoic – 20:1 TOTAL 0.1 – – 0.1 0.1 –
Eicosatrienoic 20:3(n-3) – – – – – –
Homo-c-linolenic – 20:3(n-6) 0.1 0.1 0.2 0.1 0.1 0.2
Arachidonic – 20:4(n-6) – 0.6 – – – –
Icosatetraenoic – 20:4(n-3) 0.4 0.6 0.6 0.6 0.6 0.6
Eicosapentaenoic (EPA) – 20:5(n-3) 0.5 0.5 0.6 0.6 0.6 0.6
Behenic – 22:0 0.3 0.2 0.2 0.3 0.3 0.2
Docosatetraenoic – 22:4(n-6) – – – – – –
Docosapentaenoic (DPA) – 22:5(n-6) 7.5 9.4 10.4 8.3 9.0 10.0
Docosapentaenoic – 22:5(n-3) 0.1 0.1 0.1 0.1 0.1 0.1
Docosahexaenoic (DHA) – 22:6(n-3) 40.5 46.3 44.7 43.5 44.9 45.3
Tetracosanoic – 24:0 – 0.1 – – – –
Minors (others in very low levels) 1.5 1.8 1.6 2.5 2.0 2.0
Free fatty acids 0.04 0.06 0.06 0.04 0.11 0.07
Trans fatty acids < 0.4 < 0.4 < 0.4 < 0.4 < 0.4 < 0.4
Sterols
Total sterol content (mg/kg) 4,037.5 5,097.0 3,470.3 4,510.7 3,659.1 4,473.2
Cholesterol (%) 66.0 70.8 63.9 62.2 65.8 69.1
Brassicasterol (%) 2.0 2.4 3.6 3.8 3.1 2.6
Stigmasterol (%) 6.5 5.2 17.7 11 8.4 6.9
Beta-sitosterol (%) 12.8 7.4 6.6 12.1 8.7 7.6
Delta-5-avenasterol (%) 1.6 1.4 0.9 1.1 1.9 1.5
Delta-5-campesterol (%) 1.8 1.7 2.0 3.1 2.0 2.1
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Parameter (unit)
Batch number
PB15232.3 PB16940715 NS-8107.2 PB19284.L NS-9127 NS-9126
Delta-7-stigmasterol (%) 7.0 9.6 4.6 6.0 9.3 8.3
Delta-7-avenasterol (%) 2.3 1.5 0.7 0.7 0.8 1.9
Metals (mg/kg)
Mercury < 0.005 < 0.005 < 0.005 < 0.005 < 0.005 < 0.005
Cadmium < 0.005 < 0.005 < 0.005 < 0.005 < 0.005 < 0.005
Arsenic < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01
Lead < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01
Copper < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01
Iron < 0.1 < 0.1 < 0.1 < 0.1 < 0.1 < 0.1
Tin < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01
Aluminium 0.02 0.03 < 0.02 < 0.02 < 0.02 < 0.02
Phosphorous < 1 - < 1 < 1 < 1 < 1
Nickel < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01
Microbiological analysis (CFU/g)
Total plate count 30°C (ISO 4833-1) < 10 < 40(a) < 40(a) < 10 < 10 < 10
Moulds < 10 < 10 < 10 < 10 < 10 < 10
Yeasts < 10 < 10 < 10 < 10 < 10 < 10
Coliforms 30°C (ISO 4832) < 10 < 10 < 10 < 10 < 10 < 10
E. coli detection (ISO 16649-3) Absence/1 g Absence/1 g Absence/1 g Absence/1 g Absence/1 g Absence/1 g
Staphylococcus aureus detection (ISO 6888-3) Absence/1 g Absence/1 g Absence/1 g Absence/1 g Absence/1 g Absence/1 g
Sulfite reducing anaerobic bacteria (ISO 15213) < 10 < 10 < 10 < 10 < 10 < 10
Bacillus cereus (ISO 7932) < 50 < 50 < 50 < 50 < 50 < 50
Salmonella detection (real-time PCR eq. ISO 6579) Absence/25 g Absence/25 g Absence/25 g Absence/25 g Absence/25 g Absence/25 g
Listeria monocytogenes detection (ISO 11290-1) Absence/25 g Absence/25 g Absence/25 g Absence/25 g Absence/25 g Absence/25 g
Cronobacter spp detection (q PCR eq. ISO 22964) Absent/10 g Absent/10 g Absent/10 g Absent/10 g Absent/10 g Absent/10 g
Enterobacteria detection (ISO 21528-1) Absent/10 g Absent/10 g Absent/10 g Absent/10 g Absent/10 g Absent/10 g
Mycotoxins (lg/kg)
Aflatoxin M1(b) < 0.05 < 0.05 < 0.05 < 0.05 < 0.05 < 0.05
Aflatoxin B1 < 0.07 < 0.07 < 0.07 < 0.07 < 0.07 < 0.07
Aflatoxin B2 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5
Safety of Schizochytrium sp. oil as a novel food pursuant to Regulation (EU) 2015/2283
www.efsa.europa.eu/efsajournal 11 EFSA Journal 2020;18(10):6242
Parameter (unit)
Batch number
PB15232.3 PB16940715 NS-8107.2 PB19284.L NS-9127 NS-9126
Aflatoxin G1 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5
Aflatoxin G2 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5
Fumonisin B1 < 1 < 1 < 1 < 1 < 1 < 1
Fumonisin B2 < 2 < 2 < 2 < 2 < 2 < 2
Fumonisin (sum of B1+B2) < 3 < 3 < 3 < 3 < 3 < 3
T-2 Toxin < 20 < 20 < 20 < 20 < 20 < 20
HT-2 Toxin < 20 < 20 < 20 < 20 < 20 < 20
Nivalenol < 200 < 200 < 200 < 200 < 200 < 200
Ochratoxin A < 0.05 < 0.05 < 0.05 < 0.05 < 0.05 < 0.05
Patulin < 100 < 100 < 10 < 10 < 10 < 10
Deoxynivalenol < 5 < 5 < 5 < 5 < 5 < 5
Zearalenone < 1 < 1 < 1 < 1 < 1 < 1
PCB and dioxins (upper bound results)
Sum of dioxins and furans (PCDD/F TEQ) (pg/g) 0.021 0.021 0.023 0.021 0.021 0.021
Sum of dioxins, furans and dl-PCBs (total TEQ) (pg/g) 0.024 0.024 0.026 0.024 0.024 0.024
PCB (sum 6 ndl-PCBs) (ng/g) < 0.150 < 0.150 < 0.150 < 0.150 < 0.150 < 0.150
Polycyclic aromatic hydrocarbons (lg/kg)
Benzo(a)pyrene < 0.1 < 0.1 < 0.1 < 0.1 < 0.1 < 0.1
Benzo(a)anthracene < 0.1 < 0.1 0.2 < 0.1 < 0.1 < 0.1
Chrysene < 0.1 < 0.1 0.1 < 0.1 < 0.1 < 0.1
Benzo(b)-fluoranthene < 0.1 < 0.1 < 0.1 < 0.1 < 0.1 < 0.1
Sum < 0.4 < 0.4 < 0.5 < 0.4 < 0.4 < 0.4
Pesticides
Multiresidues GC 150 ND ND ND ND ND ND
Multiresidues LC 150 ND ND ND ND ND ND
Process formed contaminants
Glycidyl fatty acid esters expressed as glycidiol (lg/kg)(c) 70 81 < 50 < 50 < 50 < 50
Sum of 3-MCPD and 3-MCPD fatty acid esters, expressed
as 3-MCPD(lg/kg)(d)
214 380 < 50 < 50 < 50 < 50
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Parameter (unit)
Batch number
PB15232.3 PB16940715 NS-8107.2 PB19284.L NS-9127 NS-9126
Marine biotoxins
Domoic acid (mg/kg) NA < 5 < 5 < 5 < 5 < 5
Okadaic acid (lg/kg) NA < 40 < 40 < 40 < 40 < 40
Dinophysistoxin-1 (lg/kg) NA < 40 < 40 < 40 < 40 < 40
Dinophysistoxin-2 (lg/kg) NA < 40 < 40 < 40 < 40 < 40
Pectenotoxin-2 (lg/kg) NA < 40 < 40 < 40 < 40 < 40
Yessotoxin (lg/kg) NA < 125 < 125 < 125 < 125 < 125
Homo yessotoxin (lg/kg) NA < 125 < 125 < 125 < 125 < 125
Azaspiracid-1 (lg/kg) NA < 40 < 40 < 40 < 40 < 40
Azaspiracid-2 (lg/kg) NA < 40 < 40 < 40 < 40 < 40
Azaspiracid-3 (lg/kg) NA < 40 < 40 < 40 < 40 < 40
13-desmethyl spirolide C (lg/kg) NA < 100 < 100 < 100 < 100 < 100
Gymnodimine (lg/kg) NA < 50 < 50 < 50 < 50 < 50
Pinnatoxin G (lg/kg) NA < 25 < 25 < 25 < 25 < 25
NA: not analysed; ND: Not detected; 3-MCPD: 3-monochloro-propanol-1,2-diol.
(a): Total plate count at 30°C was detected but at levels lower than 40 CFU/g.
(b): It is noted that aflatoxin M1 in infant formulae (IF) should not exceed 0.025 lg/kg while an LOQ of 0.05 lg/kg was used to perform the analysis. Nevertheless, considering the incorporation
rate of the NF in IF (max 87.5 mg NF/100 mL), the limit of 0.025 lg/kg in IF is expected to be respected.
(c): It is noted that glycidyl fatty acid esters in infant formulae (IF) should not exceed the maximum level (ML) of 6 lg/kg for liquid IF and FOF while a max concentration of 81 lg/kg was found in
batch PB16940715. However, considering the incorporation rate of the NF in IF (max 87.5 mg NF/100 mL), the ML of 6 lg/kg in IF is expected to be respected.
(d): It is noted that the sum of 3-MCPD and 3-MCPD esters, expressed as free 3-MCPD in IF should not exceed the maximum level (ML) of 15 lg/kg for liquid IF and FOF while a max
concentration of 380 lg/kg (sum expressed as 3-MCPD) was found in batch PB16940715. However, considering the incorporation rate of the NF in IF (max 87.5 mg NF/100 mL), the ML of 15
lg/kg in IF is expected to be respected.
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3.4.1. Stability
Stability of the NF (Schizochytrium sp. oil) during storage
The applicant recommends storing the oil under frozen conditions (–18°C) for not more than 2
years, to guarantee the properties of the product. Alternatively, a storage duration of 6 months at –
15°C may also be suitable according to the applicant. The applicant recommends storage in sealed
steel drums that are flushed with nitrogen to limit the oxygen availability. To support these
recommendations, the applicant has provided a stability study.
In this study, the laboratory made use of representative batches of the NF, which were produced 24
and 43 months before being analysed and stored under frozen conditions at temperature of –20°C and –
24°C. This range of temperature is expected to ensure the maximum temperature of –18°C is not
exceeded in practice. Two independent batches of the NF (40% S) were analysed for the two chemical
stability parameters generally measured to follow the oxidation of oils: the peroxide index and the
p-anisidine value. Additional analyses were also performed on the 40% and 50% winterised formulations
of the NF, but only 40% S results are reported in detail because this is the relevant formulation of the NF.
Results were compared with the levels found in the freshly produced samples (measurement at
time 0). In addition, the measured peroxide index and the p-anisidine value were compared with the
specification currently on the Union list (peroxide index: 5 meqO2/kg) and with the usual standards for
p-anisidine value.6
The peroxide index was found to remain within the specifications (≤ 5 meqO2/kg) when samples
were stored under proposed conditions of 2 years at –18°C, or even after a longer storage period of
43 months. It is noted that measurements performed on 40% W and 50% W formulations of the NF
also confirmed these findings. Regarding the p-anisidine value, the maximum value observed after
storage at –18°C was 8.1 (batch 1 at 24 months). Therefore, it remained below 10 under the
proposed conditions of storage.
The storage stability study confirmed that the proposed conditions of storage of the NF (maximum
2 years, deep frozen in sealed steel drums drums flushed with nitrogen) are sufficient to avoid
oxidative degradation of the NF. Furthermore, considering that the conditions of storage prevent
contact of the NF with moisture, heat, light and enzyme activity, hydrolytic degradation and/or
microbiological contamination of the NF is not expected to occur under the recommended storage
conditions. Consequently, the Panel considers that the data provided sufficient information with respect
to the stability of the NF during storage of 24 months.
Stability under the intended conditions of use (i.e. when the NF oil is powdered to be
incorporated to infant formulae and follow-on formulae)
According to the conditions of use proposed by the applicant, the NF is intended to be incorporated
(as a food ingredient) into infant formulae and follow-on formulae. The NF may undergo further
processing steps (e.g. dry powdering) before being incorporated in infant formulae and follow-on
formulae. The stability of the NF ingredient when undergoing such processing was investigated by the
applicant by means of analytical stability tests and sensory stability tests.
Analytical tests:
A batch of NF (40% S formulation) has been transformed to a dried powder by microencapsulation
by microencapsulation to simulate a product suitable for use in infant formulae. The powder has then
been flushed with nitrogen and stored for 11 months at +20°C. The applicant has reported analytical
results for oxidation indicators (peroxide index and p-anisidine value) and for DHA content measured
Table 2: Peroxide index and p-anisidine value in the stability study (storage condition –18°C)
Time (in months) 0 24 43
Peroxide index (meqO2/kg) Batch 1 (40% S) 0 1.6 –
Batch 2 (40% S) 0.9 – 2.9
p-anisidine value Batch 1 (40% S) 5.9 8.1 –
Batch 2 (40% S) 5.5 – 5.5
6 The European Pharmacopoeia defines a p-anisidine value of maximum 10 for cod liver and salmon oil. This limit can be
extrapolated to Schizochytrium sp. oil. In the US Pharmacopoeia, the limit value is 20 for Schizochytrium oil (source: https://
onlinelibrary.wiley.com/doi/full/10.1002/lite.201600013).
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in the ‘oil sample’ (the NF before powdering), in ‘Powder sample T0’ (powdered NF just after
treatment), and in ‘Powder sample T11’ (powdered NF after 11 months of storage). It is noted that the
process for obtaining the measurements for the powdered samples involved extraction of the oil from
the powder to determine the oxidation indicators and DHA content. All analyses were conducted in
external laboratories for which Certificates of Accreditations were provided. A summary of the results is
reported in the Table 3.
These results show that both peroxide index and p-anisidine values remain stable after the
powdering process and further storage of the powder. This indicates that the conditions of use would
not induce a critical oxidative degradation of the NF. It was noted that the absolute DHA content in the
powder (11.7–12.4%) is lower compared to the NF (> 40%). This is because the FA content in the
powder (28–29%) is much lower than in the NF (> 98%) due to the emulsion recipe of the powder. On
a fatty acid basis, the powdering step and the storage did not significantly alter the DHA content of
the NF under the intended conditions of use.
Sensory tests:
The applicant has also reported a sensory stability study. In this study, the laboratory tested the
storage of a powder formulation in which DHA (from the NF) had previously been incorporated. This
powder is referred to as ‘milk-based protein encapsulates’ containing DHA and is the usual form of the
DHA products ready for use as an ingredient of infant formula. Accelerated shelf-life tests were
performed on the solid powder (containing 10% DHA). Three different storage conditions were tested:
storage period of 12 weeks (at 30°C, air atmosphere), 18 weeks (at 30°C, N2-protected atmosphere)
and 12 months (at 20°C, N2-protected atmosphere).
After storage, the samples were diluted in warm milk following the normal conditions of use and
the organoleptic parameters (taste, flavour, colour) of the reconstituted milk were scored by a trained
panel.7 The applicant suggests that qualitative degradation of the product (e.g. oxidation of the oil)
can be noticed by the trained panel because oxidation of DHA-rich oils generally induces a strong
marine/fishy smell and taste. Based on predefined qualitative criteria (appearance and notes of fish,
sweet/Maillard, musty, oxidation, acidity/sharp, soapy, bitter and salt/briny), the trained panel scored
the different samples using a 5-point scale. This test as well as the scoring system was developed in-
house to assess the quality of the product. Overall, the sensory score of all samples was found to be
above the acceptance level defined in the test, in all tested conditions. This study is deemed
supportive only.
Given the results of the analytical tests and the supportive information of the sensory test, the
Panel considers that the data provided sufficient information with respect to the stability of the NF
under the proposed conditions of use.
Table 3: Peroxide index, p-anisidine value and DHA concentration in the NF before and after
powdering, and after 11 months of storage
Parameter Oil sample (NF)(a) Parameter
Powder sample
T0(b) T11(c)
Peroxide index (meqO2/kg) 0.0 Peroxide index (meqO2/kg) < 0.3 0.0
p-anisidine value 5.9 p-anisidine value n.a. 4.5
– – DHA% in powder (as TG) 12.4 11.7
– – FA% in powder (as TG) 29 27.5
DHA% (g DHA/100 g FA)
DHA% (g FA/100 g oil)
46.3
43.02
DHA% (g DHA/100 g FA)(d) 42.8 42.5
n.a.: not available; DHA: docosahexaenoic acid; FA: fatty acid; TG: triglycerides; calc: calculated.
(a): Sample of the NF under its oily form, as produced by the applicant (Batch No. PB16940715.L-N40 in Tables 1a and 1b).
(b): Powder form of the NF just after processing.
(c): Powder form of the NF after 11 months of storage at +20°C under nitrogen atmosphere.
(d): Indicative ratio calculated as [DHA% in the powder (as TG)]/[FA% in powder (as TG)].
7 From a trained sensory panel pool of 20 panel members, approximately five members were selected to perform the sensory
evaluation of the powder samples.
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3.5. Specifications
As the NF ‘Schizochytrium sp. oil’ is already authorised on the EU market, specifications for this NF
are currently presented in the Union list. The Panel verified whether the NF under assessment
complies with these specifications and subsequently assessed the need to define further specifications
for the NF under assessment.
Current specifications of the NF (Union list)
Parameters and corresponding values of the current specifications for the ‘Schizochytrium sp. oil’
are reported in Table 4. It is noted that the NF currently authorised is not strain specific. Furthermore,
the NF under assessment is currently used as a source for the authorised novel food ‘Schizochytrium
sp. oil’. Therefore, the NF under assessment shall comply with the specifications currently defined for
‘Schizochytrium sp. oil’. A comparison with the data from the batch to batch analysis of the present NF
is presented in Table 4.
According to the data submitted in the present dossier, the NF produced by the applicant complies with
the current specifications. The maximum values observed in the batch to batch analysis for the acid value,
peroxide value, moisture and volatiles, unsaponifiable and trans-fatty acids are below the limits defined in
the specifications (see Table 4). The results of the storage stability studies indicated that the specifications
are also met when the NF is stored under the proposed conditions of storage (see Section 3.4.1).
The NF under assessment complies with the specifications for ‘Schizochytrium sp. oil’ that is already
authorised on the EU market.
Discussion on additional specifications for the uses assessed in the present dossier
The applicant used a strain of Schizochytrium sp. (strain WZU477) in the production of the NF and
this strain impacts on the FA profile of the NF. Notably, concentrations of DHA range between 40.5%
and 46.3% of fatty acids content while the minimum required by the specifications is 32%. Therefore,
the applicant proposes to amend the current specifications of the Union list to consider this
particularity of the NF. The Panel considers that amending the specification to modify the minimum
concentrations of DHA (e.g. > 40% instead of 32%) is not necessary from a safety point of view.
The applicant wishes to specify that on the Union list, the authorised uses in IF and FOF are only
valid when the NF ‘Schizochytrium sp. oil’ is produced from strain WZU477. It was demonstrated that
this strain belongs to the species Schizochytrium limacinum and the Panel has considered key
information on this species to conclude on the safety of the production process. However, the
Panel did not consider data that are specific to the strain WZU477. A risk management decision needs
to be taken whether the strain WZU477 should be reported in the specifications for the NF
‘Schizochytrium sp. oil’. The Panel notes that for the NFs Schizochytrium sp. (ATCC PTA-9695) oil and
Schizochytrium sp. (T18) oil), which are currently on the Union list and authorised in IF and FOF, the
strain is mentioned in the name of the NF. However, these two strains (ATCC PTA 9695 and T18) were
not identified at species level in the Union list because this information was not used in the risk
assessment. The risk assessment for these two NFs was based on specific toxicity studies.8
Table 4: Specifications of the NF (as currently reported in the Union list) and comparison with






(based on batch to
batch analysis)
Method of analysis
Acid value (mg KOH/g) ≤ 0.5 0.28 (max) Not reported(a)
Peroxide value (meqO2/kg) ≤ 5.0 4.8 (max) Not reported(a)
Moisture and volatile (%) ≤ 0.05 0.02 (max) Not reported(a)
Unsaponifiables (%) ≤ 4.5 1.29 (max) Not reported(a)
Trans-fatty acids (%) ≤ 1.0 < 0.4 Not reported(a)
DHA-content (%) ≥ 32.0 40.5–46.3 Not reported(a)
(a): Method of analysis is not reported on the Union list.
8 The NFs Schizochytrium sp. (ATCC PTA-9695) oil and Schizochytrium sp. (T18) oil were assessed independently as separate
NFs. Specific toxicological studies performed with these NFs were considered to assess these NFs.
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It is noted that the safety assessment of the NF for its use in IF and FOF required a detailed
analysis of potential contaminants. Most of them are covered by sectoral legislation (e.g. Regulation on
infant formulae). For marine biotoxins, however, risk managers may consider amending the
specifications for the NF ‘Schizochytrium sp. oil’ when authorised in IF and FOF in order to set the
limits at the LOQ achieved in the batch to batch analysis.
The Panel notes that the p-anisidine value, which allows monitoring the secondary oxidation of oils,
has not been considered so far on the Union list for Schizochytrium oils. However, secondary oxidation
products (such as a,b-unsaturated carbonyl compounds, malonaldehyde) may be of safety concern
(Vieira et al., 2017; Kanner, 2007). Therefore, the Panel proposes to add the p-anisidine value in the
specifications for Schizochytrium sp. oils. Considering the European Pharmacopoeia values defined for
cod liver and salmon oils (2015) and the compositional data, a limit of 10 could be used for the
p-anisidine value in Schizochytrium oils.
3.6. History of use of the NF and/or of its source
3.6.1. History of use of the source
The source of the NF is a microalga belonging to the genus Schizochytrium (see full description in
Section 3.2). This genus has been used as a source of DHA-rich oils since 2003, year of the first
authorisation of the NF DHA-rich oil from Schizochytrium (Commission Decision 2003/427/EC9). The
first assessment of DHA-rich oil from Schizochytrium sp. was referring to the strain ATCC 2088 (United
Kingdom, 2002). However, several other strains have been recognised as valid sources for this NF
since 2003.
The NF under assessment is produced by the strain WZU477 (see Section 3.2). Following a
substantial equivalence dossier assessed in the Netherlands by the Committee on Safety Assessment of
Novel Foods (VNV Committee) (CBG-Meb, 2014), the production strain WZU477 was recognised as a
valid source to produce a DHA-rich oil equivalent to the original NF. DHA-rich oils produced from strain
WZU477 are therefore covered by the generic NF Schizochytrium sp. oil already reported on the Union
list. It is noted that these oils are currently not allowed to be added to IF and FOF.
Since 2015, two other strains belonging to the genus Schizochytrium were also approved for the
production of DHA-rich oils: strain ATCC PTA-9695 (2015) and strain T18 (2017). These two strains are
specifically mentioned on the Union list as part of the name of two separate NF entries. Furthermore,
the NFs ‘Schizochytrium sp. (T18) oil’ and ‘Schizochytrium sp. (ATCC PTA-9695) oil’ were also
authorised in IF and FOF. These are currently the only DHA oils from Schizochytrium authorised for use
in infant and follow-on formulae.
3.6.2. History of use of the NF
DHA-rich oils from Schizochytrium have been on the EU market since 2003. On the Union list, there
are currently four different entries referring to Schizochytrium DHA-rich oils.
Table 5: Overview of the NFs based on Schizochytrium DHA-rich oil currently present in the Union
List





Schizochytrium sp. oil 2003 Decision 2003/427/EC(a),
2009/778/EC(b),
2014/463/EU(c) and 2019/109(d)
Extension of use under
assessment for IF and FOF (so
far not authorised for this NF)
Schizochytrium sp. oil
rich in DHA and EPA
2012 Authorised by United Kingdom –
Schizochytrium sp.
(ATCC PTA-9695) oil
2015 Decision 2015/545(e) Authorised use on IF and FOF
Schizochytrium sp.
(T18) oil
2017 Authorised by Ireland Authorised use on IF and FOF
9 Commission Decision 2003/427/EC: Commission Decision of 5 June 2003 authorising the placing on the market of oil rich in DHA
(docosahexaenoic acid) from the microalgae Schizochytrium sp. as a novel food ingredient under Regulation (EC) No 258/97 of the
European Parliament and of the Council. OJ L 144, 16.6.2003, p. 13–14.
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The application under assessment is an extension of use for the first NF, referred to as generic
Schizochytrium sp. oil. This NF has been authorised since 2003 by means of Commission Decision
2003/427/EC9. It has been subject to several extensions of use which were reported in Commission
Decision 2009/778/EC10, Commission Implementing Decision 2014/463/EU11 and Commission
Implementing Regulation 2019/10912. The NF Schizochytrium sp. oil is currently authorised as a food
supplement (250 mg/day for the general population; 450 mg/day for pregnant and lactating women)
and as a food ingredient in a wide range of food categories (use levels are expressed in mg of DHA):
Milk-based drinks and similar products intended for young children (200 mg/100 g); processed
cereals-based food and baby foods for infants and young children (200 mg/100 g); food intended to
meet the expenditure of intense muscular effort (200 mg/100 g); food bearing statements on the
absence or reduced presence of gluten (200 mg/100 g); food for specific medical purposes; bakery
products (breads, rolls and sweet biscuits) (200 mg/100 g); cereal bars (500 mg/100 g); breakfast
cereals (500 mg/100 g); cooking fats (360 mg/100 g); dairy analogues except drinks (200–600 mg/100 g);
dairy products except milk-based drinks (200–600 mg/100 g); non-alcoholic beverages (including dairy
analogue and milk-based drinks) (80 mg/100 mL); spreadable fats and dressings (600 mg/100 g). An
extension of use has recently been granted for fruit and vegetables puree (100 mg/100 g).
Besides the generic NF Schizochytrium sp. oil under assessment, three other NFs are also present on
the Union list: Schizochytrium sp. oil rich in DHA and EPA; Schizochytrium sp. (ATCC PTA-9695) oil and
Schizochytrium sp. (T18) oil. These NFs were authorised for the same food categories as the generic NF
Schizochytrium sp. oil reported above, plus some additional uses. In particular, the two strain-specific
NFs Schizochytrium sp. (ATCC PTA-9695) oil and Schizochytrium sp. (T18) oil were authorised for use in
IF and FOF. These NFs can be used in accordance with Regulation (EU) 609/201313, which was
supplemented by Regulation (EU) 2016/12714.
Consequently, the use of DHA-rich oil from Schizochytrium in infant formulae and follow-on
formulae is currently authorised but is strictly restricted to DHA-rich oils produced from two specific
strains of Schizochytrium: ATCC PTA-9695 and T18.
(a): Commission Decision 2003/427/EC: Commission Decision of 5 June 2003 authorising the placing on the market of oil rich in
DHA (docosahexaenoic acid) from the microalgae Schizochytrium sp. as a novel food ingredient under Regulation (EC) No
258/97 of the European Parliament and of the Council. OJ L 144, 16.6.2003, p. 13–14.
(b): Commission Decision 2009/778/EC: Commission Decision of 22 October 2009 concerning the extension of uses of algal oil
from the micro-algae Schizochytrium sp. as a novel food ingredient under Regulation (EC) No 258/97 of the European
Parliament and of the Council. OJ L 278, 23.10.2009, p. 56–57.
(c): Commission Implementing Decision 2014/463/EU: Commission Implementing Decision of 14 July 2014 on authorising the
placing on the market of oil from the micro-algae Schizochytrium sp. as a novel food ingredient under Regulation (EC) No
258/97 of the European Parliament and of the Council and repealing Decisions 2003/427/EC and 2009/778/EC. OJ L 209,
16.7.2014, p. 55–58.
(d): Commission Implementing Regulation (EU) 2019/109 of 24 January 2019 authorising an extension of use of Schizochytrium
sp. oil as a novel food under Regulation (EU) 2015/2283 of the European Parliament and of the Council, and amending
Commission Implementing Regulation (EU) 2017/2470. OJ L23, 25.1.2019, p. 7–10.
(e): Commission Implementing Decision (EU) 2015/545 of 31 March 2015 authorising the placing on the market of oil from the
micro-algae Schizochytrium sp. (ATCC PTA-9695) as a novel food ingredient under Regulation (EC) No 258/97 of the
European Parliament and of the Council; OJ L 90, 2.4.2015, p. 7–10.
10 Commission Decision 2009/778/EC: Commission Decision of 22 October 2009 concerning the extension of uses of algal oil
from the micro-algae Schizochytrium sp. as a novel food ingredient under Regulation (EC) No 258/97 of the European
Parliament and of the Council. OJ L 278, 23.10.2009, p. 56–57.
11 Commission Implementing Decision 2014/463/EU: Commission Implementing Decision of 14 July 2014 on authorising the
placing on the market of oil from the micro-algae Schizochytrium sp. as a novel food ingredient under Regulation (EC) No
258/97 of the European Parliament and of the Council and repealing Decisions 2003/427/EC and 2009/778/EC. OJ L 209,
16.7.2014, p. 55–58.
12 Commission Implementing Regulation (EU) 2019/109 of 24 January 2019 authorising an extension of use of Schizochytrium
sp. oil as a novel food under Regulation (EU) 2015/2283 of the European Parliament and of the Council, and amending
Commission Implementing Regulation (EU) 2017/2470. OJ L23, 25.1.2019, p. 7–10.
13 Regulation (EU) No 609/2013 of the European Parliament and of the Council of 12 June 2013 on food intended for infants and
young children, food for special medical purposes and total diet replacement for weight control and repealing Council Directive
92/52/EEC, Commission Directives 96/8/EC, 1999/21/EC, 2006/125/EC and 2006/141/EC, Directive 2009/39/EC of the
European Parliament and of the Council and Commission Regulations (EC) No 41/2009 and (EC) No 953/2009 Text with EEA
relevance; OJ L 181, 29.6.2013, p. 35–56.
14 Commission Delegated Regulation (EU) 2016/127 of 25 September 2015 supplementing Regulation (EU) No 609/2013 of the
European Parliament and of the Council as regards the specific compositional and information requirements for infant formula
and follow-on formula and as regards requirements on information relating to infant and young child feeding; OJ L 25,
2.2.2016, p. 1–29.
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3.7. Proposed uses and use levels and anticipated intake
3.7.1. Target population
The NF is intended to be added to infant formula (IF) and follow-on formula (FOF). Consequently,
the target population defined by the applicant is infants and young children.
3.7.2. Proposed uses and use levels
The NF is intended to be added to IF and FOF. The applicant derived the use level directly from
Regulation (EU) 2016/127, which defines the specific compositional and information requirements for
IF and FOF. Based on the EFSA opinion on recommendations for composition of IF and FOF (EFSA,
2014a), Regulation (EU) 2016/127 states the mandatory addition of DHA to IF and FOF at levels
ranging between 4.8 and 12 mg/100 kJ (eq. 20–50 mg/100 kcal). Considering a standard energy
content of maximum 70 kcal per 100 mL of IF/FOF defined in Regulation (EU) 2016/127, the DHA level
in the reconstituted formula is expected to range between 14 and 35 mg DHA/100 mL.
Considering that the concentration of DHA in the NF is minimum 40%, the applicant defined a use
level for the NF of 35–87.5 mg NF/100 mL, to reach the target of 14–35 mg DHA/100 mL. It should be
noted that manufacturers of IF and FOF who may powder the NF and incorporate it into their formulae
shall guarantee that the concentration of DHA meets the requirement of the Regulation. This is also
the case if other sources of DHA are used in combination with the NF.
3.7.3. Anticipated intake of the NF
As the use level proposed by the applicant is directly derived from Regulation (EU) 2016/127 (see
Section 3.7.2), the intake of DHA for infants fed with IF supplemented with the NF at the proposed
use level is within the range foreseen by the Regulation.
The Panel assessed the maximum intake of NF resulting from the use of the NF in IF. The conservative
scenario where IF is the only food consumed by non-breastfed infants from 0 to 4 months was
considered, using the default value of 260 mL/kg body weight (bw) per day for high formula intakes for
infants 0–4 months (EFSA Scientific Committee, 2017). Based on the use level defined by the applicant
(maximum concentration of NF in IF of 87.5 mg/100 mL), the high intake of NF resulting from the
consumption of IF is estimated to be 227.5 mg NF/kg bw per day.15 Considering that 40% of the NF is
DHA, the estimated high daily intake of DHA from IF is 91 mg/kg bw per day.
Furthermore, two other DHA-rich oils from Schizochytrium16 are currently already authorised for use
in IF and FOF, with use levels also in line with Regulation (EU) 2016/127. Consequently, the intended
use of IF and FOF currently under assessment for the NF Schizochytrium sp. oil (from strain WZU477)
is not expected to modify the current daily intake of DHA-rich oil for infants and young children. The
NF is proposed as an alternative source of DHA for IF and FOF.
3.8. Absorption, distribution, metabolism and excretion (ADME)
The applicant did not submit specific ADME data for the NF and such data are not deemed
necessary. The digestion, absorption and metabolism of DHA have been extensively documented in the
EFSA Scientific Opinion on tolerable upper intake level of EPA, DHA and DPA (EFSA NDA Panel, 2012).
3.9. Nutritional information
The nutritional content of the NF is provided by the batch to batch analysis. The NF mainly consists
of fat in the form of triglycerides. Trans-fatty acids were not detected, and based on the acid value,
free FA are not expected to be of concern. The FA profile reveals that DHA is the predominant
compound. DHA is an essential nutrient for infants and children. The essential role of DHA for the
development of infant and young children (e.g. nervous system and the retina) has been documented
in the EFSA Scientific Opinion on nutrient requirements and dietary intakes of infants and young
children in the European Union (EFSA NDA Panel, 2013). When used in accordance with the proposed
15 The mean body weight of a 0- to 3-month infant is 5 kg and is used as a default body weight for the whole group of infants
(EFSA Scientific Committee, 2012).
16 Schizochytrium sp. (ATCC PTA-9695) oil and Schizochytrium sp. (T18) (see Section 3.6.2).
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use level, the NF can enrich the composition of IF and FOF to such extent that the latter fall within the
range targeted by the current Regulation (20–50 mg DHA/100 kcal).
The concentrations of sterols found in the NF are around 3,000–5,000 mg/kg fat. However, given
that the NF will be incorporated into IF and FOF at a maximum rate of 87.5 mg NF/100 mL, the actual
contents of sterols in IF and FOF are not considered to be of health concern.
In general, the analysis of the FA profile of the NF shows the presence of other components which
might affect the overall ratio of FA in IF and FOF. However, it falls under the responsibility of the
manufacturers to guarantee that the overall ratio of FA complies with the current regulations.
The Panel considers that taking into account the composition of the NF and the proposed
conditions of use, consumption of the NF is not nutritionally disadvantageous.
3.10. Toxicological information
3.10.1. Qualified presumption of safety (QPS)
The available evidence indicates that the source organism (Schizochytrium sp., strain WZU477)
belongs to the species Schizochytrium limacinum. In 2020, Schizochytrium limacinum was assessed by
the EFSA Panel on Biological Hazards (BIOHAZ) for its suitability to be added to the list of QPS-
recommended biological agents intentionally added to food or feed. In the opinion of BIOHAZ Panel,
Schizochytrium limacinum was identified as a synonym of Aurantiochytrium limacinum. The BIOHAZ
Panel considered the identity, the body of knowledge and potential safety concerns of this
microorganism. The literature searches performed did not provide any evidence for a safety concern
for human or animal health for any use of S. limacinum. The BIOHAZ Panel concluded that
S. limacinum may be recommended for the QPS list with the qualification ‘for production purposes
only’ (EFSA BIOHAZ Panel, 2020).
3.10.2. Absence of marine biotoxins
The absence of marine biotoxins was demonstrated in the assessment of the composition of the NF
(see Section 3.4). The Panel verified whether the LOQs used in the reported analysis of the common
marine biotoxins were sufficiently low compared to the acute reference dose (ARfD) of the respective
biotoxins (EFSA CONTAM Panel, 2009). It was found that the theoretical intakes resulting from the
occurrence of marine biotoxins at their respective LOQs remain well below the respective ARfD of the
corresponding biotoxins (see Table 6). It is concluded that the reported LOQs are sufficiently low to
ensure consumer safety. Consequently, they can be considered in the specifications.
Table 6: Theoretical exposure to marine biotoxins considering the LOQs and comparison with the
respective acute reference doses (ARfD)
Marine biotoxin LOQ(a)
Theoretical maximal biotoxin






Azaspiracids 40 lg/kg 0.0091 0.2 22
Pectenotoxins 40 lg/kg 0.0091 0.8 88
Yessotoxins 125 lg/kg 0.0284 25 879
Amnesic shellfish toxin,
domoic acid
5 mg/kg 1.1375 30 26
Paralytic shellfish toxin,
saxitoxin
n.r. – 0.5 –
Okadaic acid 40 lg/kg 0.0091 0.3 33
LOQ: Limit of Quantification ARfD: Acute reference dose; n.r.: not reported.
(a): Limit of Quantification reached in the compositional analysis of the NF (see Section 3.4).
(b): Considering the critical exposure of non-breastfed infant resulting in 227.5 mg NF/kg bw per day and respective LOQs of
biotoxins.
(c): Acute reference dose assessed in EFSA CONTAM Panel (2009).
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3.10.3. Toxicity of DHA oils derived from Schizochytrium sp
No toxicity studies that were conducted with the novel food under assessment (DHA-rich oil
produced from strain WZU477 of Schizochytrium sp.) have been provided.
However, the toxicity of DHA-rich algal oils produced from different strains of Schizochytrium sp.
has been well documented over the last decades. Several guideline compliant studies, including
bacterial reverse mutation tests, in vitro chromosomal aberration tests, in vivo mammalian cell
micronucleus tests, subchronic toxicity studies with rats and developmental and reproductive toxicity
studies with rats, were performed with various forms of DHA algal oils from Schizochytrium sp. Most of
these studies were assessed and used to conclude on the safety of NFs evaluated in former
authorisation frameworks. Notably two studies performed with DHA oil produced from strain ATCC
PTA-9695 (Fedorova-Dahms et al., 2011 and an unpublished study) were performed to support the
authorisation of the NF Schizochytrium sp. (ATCC PTA-9695) in infant and follow-on formula. These
studies have been assessed by the UK competent authority in 2014 (United Kingdom, 2014). Similarly,
two other studies performed with DHA oil produced from strain T18 (Schmitt et al., 2012a,b) have also
been considered by the UK competent authority in support of the authorisation of the NF
Schizochytrium sp. (T18) in infant and follow-on formula in 2017 (United Kingdom, 2017). In addition,
two other studies (Lewis et al., 2016; Falk et al., 2017), performed with DHA oils from unspecified
strains of Schizochytrium sp., have been considered in the assessment of Anses (2018).
In all previous assessments, the competent authorities concluded that there were no concerns with
regard to genotoxicity and subchronic toxicity of the tested materials. Further studies found in the
literature indicate the same outcome for a diversity of DHA oils produced from other strains of
Schizochytrium sp. which have a longer history of use (Hammond et al., 2001a, 2001b, 2002; Blum
et al., 2007; Kroes et al., 2003; Abril et al., 2003).
3.10.4. Summary
Even though toxicological tests were not conducted with the NF that is assessed in the present
opinion, the Panel considers that, given the results on toxicity in studies performed with various forms
of DHA oils derived from Schizochytrium sp., given the QPS status of the source of the NF and
considering data on the production process and on the composition of the NF (absence of viable cells,
absence of marine biotoxins), there are no concerns with regard to toxicity of the NF.
3.11. Allergenicity
The applicant provided a proximate analysis of the NF, which indicates that proteins were below the
LOQ (0.01 g/kg). The Panel considers that the NF is unlikely to trigger adverse allergic reactions in the
general population or subgroups thereof under the proposed conditions of use.
4. Discussion
The NF, which is the subject of the application, is a DHA-rich oil derived from Schizochytrium sp.
(strain WZU477). The available evidence indicates that the source organism (Schizochytrium sp., strain
WZU477) belongs to the species Schizochytrium limacinum. The Panel considers that the information
provided on the composition of the NF is sufficient and does not raise safety concerns.
In 2020, Schizochytrium limacinum was assessed by the EFSA BIOHAZ Panel and attributed the QPS
status with the qualification ‘for production purposes’, which implies the absence of viable Schizochytrium
cells in the final product. The NDA Panel considers that based on the information provided on the
production process, the microalga is not expected to survive the manufacturing process. The
Panel considers that the production process is sufficiently described and does not raise safety concerns.
The applicant intends to market the NF as an ingredient for IF and FOF to meet the requirement of
Regulation (EU) 2016/127. Consequently, the proposed use levels (defined on DHA basis) are the same
as for the other DHA-rich oils from Schizochytrium sp. which are currently on the market and
authorised for supplementing DHA in IF and FOF. Therefore, the intake of DHA resulting from the
proposed use is not expected to modify the current situation as regards the total intake of DHA in
infants and young children.
Toxicological tests conducted with the NF were not performed. However, based on the available
toxicological data on various forms of DHA oils derived from Schizochytrium sp., the QPS status of the
source of the NF, the production process and the composition of the NF (absence of viable cells, absence
of marine biotoxins), the Panel considers that there are no concerns with regard to toxicity of the NF.
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5. Conclusions
The Panel concludes that the NF, i.e. Schizochytrium sp. oil (produced from the strain WZU477
belonging to species Schizochytrium limacinum), is safe under the proposed conditions of use. The
target population is infants and young children.
The Panel could not have reached the conclusion on the safety of the NF under the proposed
conditions of use without the following data claimed as proprietary by the applicant:
• Original submitted data: Annex I (NF application 2012); detailed description of the production
process; Annex II (chemical characteristics); Annex III (fatty acid analysis); Annex IV (sterol
analysis); Annex V (heavy metals analysis); Annex VI (PAH analysis); Annex VII (mycotoxin
analysis); Annex VIII (dioxin, dioxin like, PCB, pesticides analysis); Annex IX (microbiological
analysis); Annex XI (retrospective stability study); Annex XII (analytical lab certificates);
Appendix B.2 (compositional data NF);
• Additional submitted data: Annex IV (protein analysis); Annex VI (3 MCPD & glycidyl ester
analyses); Annex VII (physicochemical analysis); Annex VIII (microbiological analysis); Annex
IX (heavy metals analysis); Annex X (mycotoxin analysis); Annex XI (PAH, dioxin and dioxin-
like contaminants analysis); Annex XII (fatty acid profile analysis); Annex XIV (sterol
composition analysis); Annex XVII (hydrolytic rancidity analysis over time); Annex 1 (marine
biotoxin analysis); Annex 3 (stability study); Annex I (certificate of analysis).
6. Steps taken by EFSA
1) Letter from the European Commission to the European Food Safety Authority with the
request for a scientific opinion on the safety of Schizochytrium sp. oil as a novel food Ref.
Ares(2019)4000797, dated 24 June 2019.
2) On 24/06/2019, a valid application on Schizochytrium sp. oil as a novel food, which was
submitted by Progress Biotech bv, was made available to EFSA by the European Commission
through the Commission e-submission portal (NF 2019/0983) and the scientific evaluation
procedure was initiated.
3) On 18/11/2019, EFSA requested the applicant to provide additional information to
accompany the application and the scientific evaluation was suspended.
4) On 19/06/2020, additional information was provided by the applicant and the scientific
evaluation was restarted.
5) During its meeting on 31 August 2020, the NDA Panel, having evaluated the data, adopted a
scientific opinion on the safety of Schizochytrium sp. oil as a NF pursuant to Regulation (EU)
2015/2283.
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